Immunocore Holdings plc Capital Expenditures
Immunocore Holdings plc (IMCR) reported Capital Expenditures of $2.57 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-06
- Immunocore Holdings plc payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $786.00K, a 89.86% increase year-over-year.
- Immunocore Holdings plc payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $1.78M, a 497.65% increase year-over-year.
- Immunocore Holdings plc payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $2.88M, a 19.64% decline year-over-year.
- Immunocore Holdings plc payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $748.00K, a 9.66% decline year-over-year.
- Immunocore Holdings plc payments to acquire property, plant, and equipment for fiscal 2025 was $4.34M, a 16.10% decline from fiscal 2024.
- Immunocore Holdings plc payments to acquire property, plant, and equipment for fiscal 2024 was $5.17M, a 4.65% decline from fiscal 2023.
- Immunocore Holdings plc payments to acquire property, plant, and equipment for fiscal 2023 was $5.42M, a 146.26% increase from fiscal 2022.
- Immunocore Holdings plc payments to acquire property, plant, and equipment for fiscal 2022 was $2.20M, a 58.95% increase from fiscal 2021.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $786.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $2.57M 10-Q · filed 2026-08-06 | $5.45M derived: sum of 3 quarters · filed 2026-08-06 | $6.20M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.78M 10-Q · filed 2026-05-06 | $4.66M derived: sum of 2 quarters · filed 2026-05-06 | $5.41M derived: sum of 3 quarters · filed 2026-05-06 | $5.82M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $2.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $3.63M derived: sum of 2 quarters · filed 2026-02-25 | $4.04M derived: sum of 3 quarters · filed 2026-08-06 | $4.34M 10-K · filed 2026-02-25 |
| 2025-09-30 | $748.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.16M derived: sum of 2 quarters · filed 2026-08-06 | $1.46M 10-Q · filed 2025-11-06 | $5.04M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $414.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $712.00K 10-Q · filed 2026-08-06 | $4.30M derived: sum of 3 quarters · filed 2026-08-06 | $5.12M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $298.00K 10-Q · filed 2026-05-06 | $3.88M derived: sum of 2 quarters · filed 2026-05-06 | $4.71M derived: sum of 3 quarters · filed 2026-05-06 | $5.04M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $3.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $4.41M derived: sum of 2 quarters · filed 2026-02-25 | $4.74M derived: sum of 3 quarters · filed 2026-02-25 | $5.17M 10-K · filed 2026-02-25 |
| 2024-09-30 | $828.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.16M derived: sum of 2 quarters · filed 2025-11-06 | $1.59M 10-Q · filed 2025-11-06 | $2.41M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $331.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $761.00K 10-Q · filed 2025-08-07 | $1.58M derived: sum of 3 quarters · filed 2026-02-25 | $1.79M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $430.00K 10-Q · filed 2025-05-07 | $1.25M derived: sum of 2 quarters · filed 2026-02-25 | $1.46M derived: sum of 3 quarters · filed 2026-02-25 | $2.85M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $817.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $1.03M derived: sum of 2 quarters · filed 2026-02-25 | $2.42M derived: sum of 3 quarters · filed 2026-02-25 | $5.42M 10-K · filed 2026-02-25 |
| 2023-09-30 | $212.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $1.61M derived: sum of 2 quarters · filed 2024-11-06 | $4.61M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $1.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $4.40M 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $3.00M 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $2.20M 10-K · filed 2025-02-26 | |||
| 2021-12-31 | $1.39M 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |